The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

In April, the CDC’s influential Advisory Committee on Immunization Practices recommended expanding RSV vaccination to ...

The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV. It also recommends the shot during ...

Child mortality has been halved in the last 25 years. Building on this progress, new innovations in immunization are working ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

New data hint at a role for the AS01 adjuvant in vaccines for herpes zoster and respiratory syncytial virus in protecting ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

For older adults who express more confidence in vaccine safety than younger groups, the past few months have brought welcome ...

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...